Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 658-661

  Tsao, Anne S ^a   Liu, Suyu ^a   Lee, J Jack ^a   Alden, Christine M ^a   Blumenschein, George R ^a   Herbst, Roy ^c   Davis, Suzanne E ^a   Kim, Edward ^a   Lippman, Scott ^a   Heymach, John ^a   Tran, Hai ^a   Tang, Ximing ^a,b   Wistuba, Ignacio ^a,b   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

EGFR gene amplification; EGFR mutation; Non small cell lung cancer; Vandetanib

Indexed keywords

ALKALINE PHOSPHATASE; B RAF KINASE; BEXAROTENE; ELECTROLYTE; EOTAXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INTERLEUKIN 9; K RAS PROTEIN; LIVER ENZYME; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SORAFENIB; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VANDETANIB; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; INFECTION; KIDNEY FAILURE; LUNG COMPLICATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION;

EID: 84876401363     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828d08ae     Document Type: Article

References (15)

1. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
2. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:1059-1066.
3. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-626.
4. Heymach J V, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as frst-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-5415.
5. Qi WX, Tang LN, He AN, et al. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 2011;189:437-443.
6. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of ben-eft from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009;15:3600-3609.
7. Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profling identifes markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-2179.
8. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13:827-837.
9. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of beneft for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:193-201.
10. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus geftinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009;27:2523-2529.
11. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-1121.
12. Kiura K, Nakagawa K, Shinkai T, et al. A randomized, double-blind, phase IIa dose-fnding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3:386-393.
13. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
14. Zhu CQ, da Cunha Santos G, Ding K, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
15. Ichihara E, Ohashi K, Takigawa N, et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 2009;69:5091-5098.